| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
|
Purity: ≥98%
Heparin sodium (150,160,170,180unit/mg) is a sulfated polysaccharide that is a member of the glycosaminoglycan family. It interacts with various proteins to perform a variety of significant biological functions. Because heparin can quicken the pace at which antithrombin inhibits serine proteases in the blood coagulation cascade, it is frequently used as an anticoagulant medication. Heparin and heparan sulfate, which share structural similarities, are complex linear polymers consisting of a mixture of chains with varying lengths and sequences.
| Targets |
Antithrombin III
|
|
|---|---|---|
| ln Vitro |
Heparin is a potent anticoagulant medication because it can quicken the pace at which antithrombin inhibits serine proteases in the cascade of blood coagulation. Heparin and heparan sulfate, which share structural similarities, are complex linear polymers consisting of a mixture of chains with varying lengths and sequences. Peptides with a corresponding binding site that has a high positive charge density exhibit the strongest interactions with heparin. Along the polysaccharide backbone, heparin and heparan sulfate primarily show linear helical secondary structures with carboxyl and sulfo groups exhibited at specific orientations and intervals. Heparin and DNA are both highly charged linear polymers that exhibit polyelectrolyte behavior. Heparin is thought to work as an anticoagulant mainly by interacting with AT III to improve AT-III-mediated inhibition of blood coagulation factors, such as factor Xa and thrombin. The ternary complex formed by heparin's binding to AT III and thrombin increases the bimolecular rate constant for thrombin inhibition by a factor of 2000. The main place to find heparin is in the tissue mast cell granules, which are intimately related to the immune response. Heparin interacts extensively with FGFR-1 and FGF-2 to stabilize the binding of these two proteins. Additionally, heparin interacts with FGFR-1 of the nearby FGF–FGFR complex, which appears to encourage FGFR dimerization[1].
|
|
| ln Vivo |
|
|
| Animal Protocol |
C57BL/6J mice
100, 500, or 2500 units/kg i.p. |
|
| References |
| Molecular Formula |
(C12H16NS2NA3)20
|
|
|---|---|---|
| Molecular Weight |
6000-20000
|
|
| CAS # |
9041-08-1
|
|
| Related CAS # |
Heparin sodium salt;9041-08-1;Heparin Lithium salt;9045-22-1;Heparin;9005-49-6
|
|
| SMILES |
C1N(CN(CN1CCO)CC[O-])CCO.[Na+]
|
|
| InChi Key |
YOMTXLQWRQUKAK-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C9H20N3O3.Na/c13-4-1-10-7-11(2-5-14)9-12(8-10)3-6-15;/h13-14H,1-9H2;/q-1;+1
|
|
| Chemical Name |
sodium;2-[3,5-bis(2-hydroxyethyl)-1,3,5-triazinan-1-yl]ethanolate
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|---|
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
